[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360708-105":59,"doc-detail-360708-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tanshinone-iia-in-breast-cancer-molecular-mechanisms-structural-optimization-and-translational-challenges","Tanshinone IIA in Breast Cancer - Molecular mechanisms, structural optimization and translational challenges","","Tanshinone IIA (Tan IIA), a lipophilic abietane-type diterpenoid from Salvia miltiorrhiza, shows distinct anticancer mechanistic features in breast cancer. Evidence from breast cancer models indicates that Tan IIA can induce apoptosis, stabilize G-quadruplex DNA, disrupt mitochondrial oxidative phosphorylation, and inhibit estrogen receptor α/ERBB2-driven signaling. It also modulates epigenetic regulators such as lysine demethylase 1A and promotes ferroptosis via redox homeostasis disruption. Translation is limited by poor aqueous solubility, rapid metabolic conversion and low oral bioavailability (~2–6% in rats), partly addressed by structural optimization and nanoscale delivery.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tanshinone-iia-in-breast-cancer-molecular-mechanisms-structural-optimization-and-translational-challenges/360708/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tanshinone-iia-in-breast-cancer-molecular-mechanisms-structural-optimization-and-translational-challenges/360708.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What anticancer mechanisms are reported for Tanshinone IIA in breast cancer?","Question",{"text":113,"@type":114},"Reported mechanisms include induction of apoptosis, stabilization of G-quadruplex DNA, disruption of mitochondrial oxidative phosphorylation, inhibition of ERα/HER2-driven signaling, modulation of lysine demethylase 1A, and promotion of ferroptosis by disturbing redox homeostasis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why does Tan IIA have limited translational potential?",{"text":118,"@type":114},"Limitations include poor aqueous solubility, rapid metabolic conversion, and low oral bioavailability (about ~2–6% in rats), which hinder clinical translation.",{"name":120,"@type":111,"acceptedAnswer":121},"How are the main limitations of Tan IIA being addressed?",{"text":122,"@type":114},"Recent efforts include structural optimization and nanoscale delivery systems, which have partially improved solubility and delivery-related barriers.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360708,1790658578,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ONCOLOGY REPORTS 56: 150, 2026  \nTanshinone IIAin breast cancer: Molecular mechanisms, structural optimization and translational challenges (Review)  \nXIUXIALI and LINLIN FENG  \nDepartment of Breast Diseases, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China  \nReceived March 9, 2026; Accepted June 8, 2026  \nDOI: 10. 3892/or.2026.9155  \nAbstract. Tanshinone IIA (Tan IIA), a lipophilic abietane‑type diterpenoid isolated from Salvia miltiorrhiza , exhibits a set of mechanistic features that distinguish it from numerous other natural products. Recent studies in breast cancer models have revealed that Tan IIA not only induces apoptosis but also targets several cancer‑relevant vulnerabilities, including the stabiliza‑ tion of G‑quadruplex (G4) DNA structures, the disruption of mitochondrial oxidative phosphorylation and the inhibition of estrogen receptor α/human epidermal growth factor receptor 2‑driven signaling. Tan IIA further modulates epigenetic regu‑ lators such as lysine demethylase 1A and promotes ferroptosis by disturbing redox homeostasis. These mechanisms support the multifaceted anticancer potential of Tan IIA; however, their relative contribution appears to be highly dependent on concentration, formulation, derivative structure and breast cancer subtype. Nevertheless, Tan IIA suffers from poor aqueous solubility, rapid metabolic conversion and low oral bioavailability, reported to be ~2‑6% in rats, which hinder its translational prospects. Recent efforts involving structural optimization and nanoscale delivery systems have partially addressed these limitations. Overall, this review integrates  \ncurrent mechanistic and pharmacological evidence and high‑ lights both the therapeutic promise and the critical barriers that must be overcome for the successful development of Tan IIA‑based interventions in breast cancer. High‑micromolar in vitro findings, particularly those related to reactive oxygen species‑dependent cytotoxicity, ferroptosis or G4 stabilization, should be interpreted cautiously unless supported by pharma‑ cokinetic, tumor‑exposure and in vivo target‑engagement data.  \nContents  \n1. Introduction  \n2. Chemical and pharmacological basis of Tan IIA  \n3. Mechanisms of Tan IIA in breast cancer  \n4. Optimization of derivatives and delivery system  \n5. Structure‑activity relationships of Tan IIA and its derivatives 6. Conclusion, safety considerations and perspectives  \nCorrespondence to: Mrs. Linlin Feng, Department of Breast Diseases, Weifang People's Hospital, 151 Guangwen Street, Kuiwen, Weifang, Shandong 261041, P.R. China  \nE‑mail: [17853662227@163.com](17853662227@163.com)  \nAbbreviations: ABC, ATP‑binding cassette; ADC, antibody‑drug conjugate; ADME, absorption, distribution, metabolism and excretion; AKT, protein kinase B; AMPK, AMP‑activated protein kinase; ATA, acetyltanshinone IIA; BCSCs, breast cancer stem cells; Bcl‑2, B‑cell lymphoma 2; Bcl‑xL, B‑cell lymphoma‑extra large; BCRP, breast cancer resistance protein; BrdU, 5‑bromo‑2'‑deoxyuridine; CD44+/CD24‑, cluster of differentiation 44 positive/cluster of differentiation 24 low or negative; CHOP, C/EBP homologous protein; CM, celastrol; Dox, doxorubicin; EGFR, epidermal growth factor receptor; EMT, epithelial‑mesenchymal transition; ERα , estrogen receptor α; ERK, extracellular signal‑regulated kinase; ESR1, estrogen receptor 1; FES, fluoroestradiol; G4, G‑quadruplex; GADD153, growth arrest and DNA damage‑inducible protein 153; GPER, G protein‑coupled estrogen receptor; GREB1, growth regulating estrogen receptor binding 1; HER2, human epidermal growth factor receptor 2; HIF‑1α , hypoxia‑inducible factor 1α; HTA, hydroquinone tanshinone IIA; IC50 , half‑maximal inhibitory concentration; IL‑6, interleukin 6; JNK, c‑Jun N‑terminal kinase;  \nKDM1A, lysine demethylase 1A; MAPK, mitogen‑activated protein kinase; MRP1, multidrug resistance‑associated protein 1; MSN, mesoporous silica nanoparticles; MYC, MYC proto‑oncogene; NF‑κB, nuclear factor ","cbCailTpUmC0oxeX","https://ap.wps.com/l/cbCailTpUmC0oxeX","pdf",2997712,13,"English","# Introduction\n## Chemical and pharmacological basis of Tan IIA\n## Mechanisms of Tan IIA in breast cancer\n## Optimization of derivatives and delivery system\n## Structure-activity relationships and conclusion","[{\"question\":\"What anticancer mechanisms are reported for Tanshinone IIA in breast cancer?\",\"answer\":\"Reported mechanisms include induction of apoptosis, stabilization of G-quadruplex DNA, disruption of mitochondrial oxidative phosphorylation, inhibition of ERα/HER2-driven signaling, modulation of lysine demethylase 1A, and promotion of ferroptosis by disturbing redox homeostasis.\"},{\"question\":\"Why does Tan IIA have limited translational potential?\",\"answer\":\"Limitations include poor aqueous solubility, rapid metabolic conversion, and low oral bioavailability (about ~2–6% in rats), which hinder clinical translation.\"},{\"question\":\"How are the main limitations of Tan IIA being addressed?\",\"answer\":\"Recent efforts include structural optimization and nanoscale delivery systems, which have partially improved solubility and delivery-related barriers.\"}]","Tanshinone IIA in Breast Cancer - Molecular mechanisms, structural optimization and translational challenges | PDF",1790141275,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e991b37420c4bf22e88254e7f3d073d.webp",983,1357,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/191a87193ac71aeb04fa9458f7857777.webp",982,1356,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0a80b9bea10b462ba3ad53e3dda9f7e.webp",981,1354,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0eb4054b9a92d07c5c310101f6419b8.webp",980,1353]